全文获取类型
收费全文 | 4877篇 |
免费 | 361篇 |
国内免费 | 14篇 |
专业分类
耳鼻咽喉 | 36篇 |
儿科学 | 178篇 |
妇产科学 | 136篇 |
基础医学 | 575篇 |
口腔科学 | 72篇 |
临床医学 | 634篇 |
内科学 | 919篇 |
皮肤病学 | 51篇 |
神经病学 | 466篇 |
特种医学 | 105篇 |
外科学 | 724篇 |
综合类 | 67篇 |
一般理论 | 26篇 |
预防医学 | 550篇 |
眼科学 | 77篇 |
药学 | 300篇 |
中国医学 | 8篇 |
肿瘤学 | 328篇 |
出版年
2023年 | 70篇 |
2022年 | 121篇 |
2021年 | 282篇 |
2020年 | 125篇 |
2019年 | 241篇 |
2018年 | 250篇 |
2017年 | 154篇 |
2016年 | 132篇 |
2015年 | 140篇 |
2014年 | 193篇 |
2013年 | 275篇 |
2012年 | 354篇 |
2011年 | 425篇 |
2010年 | 182篇 |
2009年 | 166篇 |
2008年 | 265篇 |
2007年 | 231篇 |
2006年 | 213篇 |
2005年 | 213篇 |
2004年 | 194篇 |
2003年 | 139篇 |
2002年 | 139篇 |
2001年 | 56篇 |
2000年 | 38篇 |
1999年 | 37篇 |
1998年 | 31篇 |
1997年 | 18篇 |
1996年 | 21篇 |
1995年 | 21篇 |
1994年 | 15篇 |
1993年 | 20篇 |
1992年 | 41篇 |
1991年 | 45篇 |
1990年 | 40篇 |
1989年 | 25篇 |
1988年 | 26篇 |
1987年 | 35篇 |
1986年 | 27篇 |
1985年 | 15篇 |
1984年 | 17篇 |
1982年 | 14篇 |
1981年 | 12篇 |
1980年 | 19篇 |
1979年 | 28篇 |
1978年 | 11篇 |
1977年 | 11篇 |
1976年 | 14篇 |
1973年 | 10篇 |
1971年 | 11篇 |
1970年 | 11篇 |
排序方式: 共有5252条查询结果,搜索用时 17 毫秒
31.
32.
Effect of a cognitive behavioral intervention on reducing symptom severity during chemotherapy. 总被引:4,自引:0,他引:4
Charles Given Barbara Given Mohammad Rahbar Sangchoon Jeon Ruth McCorkle Bernadine Cimprich Andrzej Galecki Sharon Kozachik Albert Brady Mary Jo Fisher-Malloy Kathy Courtney Elizabeth Bowie 《Journal of clinical oncology》2004,22(3):507-516
PURPOSE: To describe a randomized trial of a cognitive behavioral intervention on reducing symptom severity among patients diagnosed with solid tumors and undergoing a first course of chemotherapy and to determine whether the intervention had an additive or interactive effect on symptom severity in the presence of supportive care medications. PATIENTS AND METHODS: Patients (N = 237) were accrued from comprehensive and community cancer centers, interviewed, and randomly assigned to either the experimental intervention (n = 118) or conventional care (n = 119). A symptom severity index, based on summed severity scores across 15 symptoms, was the primary outcome. Each patient's site of cancer, stage at diagnosis, chemotherapy protocols, and use of supportive medications were learned from medical records. RESULTS: Groups were equivalent at baseline, and attrition by characteristics by group was not different. The proportion of patients not receiving chemotherapy at 10 and 20 weeks did not differ by group. At the 10- and 20-week observations, there was a significant interaction between the experimental group and baseline symptom severity. Patients in the experimental group who entered the trial with higher symptom severity reported significantly lower severity at 10 and 20 weeks. Controlling for chemotherapy treatment status at follow-up and supportive care medications did not alter the effect of the experimental intervention. CONCLUSION: Compared with conventional care alone, the experimental intervention was effective among patients who entered the trial with higher levels of symptom severity. Age, sex, site or stage of cancer, and supportive medications did not modify the effect of this cognitive behavioral intervention on symptom severity. 相似文献
33.
34.
Effect of posaconazole on cytochrome P450 enzymes: a randomized, open-label, two-way crossover study 总被引:3,自引:0,他引:3
D. Wexler R. Courtney W. Richards C. Banfield J. Lim M. Laughlin 《European journal of pharmaceutical sciences》2004,21(5):139-653
Posaconazole is an antifungal with a wide-spectrum of activity against common and emerging fungal pathogens. In this randomised, open-label, two-way crossover study, the potential for drug interactions with posaconazole via the cytochrome P450 (CYP450) enzyme pathway was evaluated. Thirteen subjects received posaconazole tablets (2×100 mg) once daily for 10 days or no treatment; following a 14-day washout period, subjects were crossed over to the alternate treatment. The inhibition spectra of posaconazole were examined using a cocktail of the following probe substrates: caffeine (CYP1A2), tolbutamide (CYP2C8/9), dextromethorphan (CYP2D6 and total CYP3A4), chlorzoxazone (CYP2E1), and midazolam (hepatic CYP3A4). Except for midazolam, which was intravenously infused on Day 10, the cocktail probes were administered simultaneously on Day 9 during both treatment periods. Blood and urine samples were collected at specified times to quantitate probe substrates and/or metabolites. Based on insignificant differences in mean probe ratios, posaconazole did not inhibit CYP1A2, 2C8/9, 2D6, or 2E1. However, the midazolam AUC(tf) was higher in the posaconazole than no-treatment group (93.4 ng h/ml versus 51.4 ng h/ml, P<0.01), indicating inhibition of hepatic CYP3A4. Drug interactions mediated by various CYP450 are common with the currently available triazole antifungals, however these results suggest that posaconazole may have an improved and more narrow drug interaction profile (CYP3A4 only) compared with other triazoles. 相似文献
35.
Dickens Otieno Onyango Marianne A. B. van der Sande Courtney M. Yuen Jerphason Mecha Daniel Matemo Elizabeth Oele John Kinuthia Grace JohnStewart Sylvia M. LaCourse 《Journal of the International AIDS Society》2022,25(8)
IntroductionIsoniazid preventive therapy (IPT) can reduce the risk of tuberculosis (TB) in children living with HIV (CLHIV), but data on the outcomes of the IPT cascade in CLHIV are limited.MethodsWe evaluated the IPT cascade among CLHIV aged <15 years and newly enrolled in HIV care in eight HIV clinics in western Kenya. Medical record data were abstracted from September 2015 through July 2019. We assessed the proportion of CLHIV completing TB symptom screening, IPT eligibility assessment, IPT initiation and completion. TB incidence rate was calculated stratified by IPT initiation and completion status. Risk factors for IPT non‐initiation and non‐completion were assessed using Poisson regression with generalized linear models.ResultsOverall, 856 CLHIV were newly enrolled in HIV care, of whom 98% ([95% CI 97–99]; n = 841) underwent screening for TB symptoms and IPT eligibility. Of these, 13 (2%; 95% CI 1–3) were ineligible due to active TB and 828 (98%; 95% CI 97–99) were eligible. Five hundred and fifty‐nine (68%; 95% CI 64–71) of eligible CLHIV initiated IPT; median time to IPT initiation was 3.6 months (interquartile range [IQR] 0.5–10.2). Overall, 434 (78%; 95% CI 74–81) IPT initiators completed. Attending high‐volume HIV clinics (aRR = 2.82; 95% CI 1.20–6.62) was independently associated with IPT non‐initiation. IPT non‐initiation had a trend of being higher among those enrolled in the period 2017–2019 versus 2015–2016 (aRR = 1.91; 0.98–3.73) and those who were HIV virally non‐suppressed (aRR = 1.90; 95% CI 0.98–3.71). Being enrolled in 2017–2019 versus 2015–2016 (aRR = 1.40; 1.01–1.96) was independently associated with IPT non‐completion. By 24 months after IPT screening, TB incidence was four‐fold higher among eligible CLHIV who never initiated (8.1 per 1000 person years [PY]) compared to CLHIV who completed IPT (2.1 per 1000 PY; rate ratio [RR] = 3.85; 95% CI 1.08–17.15), with a similar trend among CLHIV who initiated but did not complete IPT (8.2/1000 PY; RR = 4.39; 95% CI 0.82–23.56).ConclusionsDespite high screening for eligibility, timely IPT initiation and completion were suboptimal among eligible CLHIV in this programmatic cohort. Targeted programmatic interventions are needed to address these drop‐offs from the IPT cascade by ensuring timely IPT initiation after ruling out active TB and enhancing completion of the 6‐month course to reduce TB in CLHIV. 相似文献
36.
Laura M. Carlson Michelle Angrish Avanti V. Shirke Elizabeth G. Radke Brittany Schulz Andrew Kraft Richard Judson Grace Patlewicz Robyn Blain Cynthia Lin Nicole Vetter Courtney Lemeris Pamela Hartman Heidi Hubbard Xabier Arzuaga Allen Davis Laura V. Dishaw Ingrid L. Druwe Hillary Hollinger Ryan Jones J. Phillip Kaiser Lucina Lizarraga Pamela D. Noyes Michele Taylor Andrew J. Shapiro Antony J. Williams Kristina A. Thayer 《Environmental health perspectives》2022,130(5)
Background: Per- and polyfluoroalkyl substances (PFAS) are a large class of synthetic (man-made) chemicals widely used in consumer products and industrial processes. Thousands of distinct PFAS exist in commerce. The 2019 U.S. Environmental Protection Agency (U.S. EPA) Per- and Polyfluoroalkyl Substances (PFAS) Action Plan outlines a multiprogram national research plan to address the challenge of PFAS. One component of this strategy involves the use of systematic evidence map (SEM) approaches to characterize the evidence base for hundreds of PFAS.Objective: SEM methods were used to summarize available epidemiological and animal bioassay evidence for a set of PFAS that were prioritized in 2019 by the U.S. EPA’s Center for Computational Toxicology and Exposure (CCTE) for in vitro toxicity and toxicokinetic assay testing.Methods: Systematic review methods were used to identify and screen literature using manual review and machine-learning software. The Populations, Exposures, Comparators, and Outcomes (PECO) criteria were kept broad to identify mammalian animal bioassay and epidemiological studies that could inform human hazard identification. A variety of supplemental content was also tracked, including information on in vitro model systems; exposure measurement–only studies in humans; and absorption, distribution, metabolism, and excretion (ADME). Animal bioassay and epidemiology studies meeting PECO criteria were summarized with respect to study design, and health system(s) were assessed. Because animal bioassay studies with exposure duration (or reproductive/developmental study design) were most useful to CCTE analyses, these studies underwent study evaluation and detailed data extraction. All data extraction is publicly available online as interactive visuals with downloadable metadata.Results: More than 40,000 studies were identified from scientific databases. Screening processes identified 44 animal and 148 epidemiology studies from the peer-reviewed literature and 95 animal and 50 epidemiology studies from gray literature that met PECO criteria. Epidemiological evidence (available for 15 PFAS) mostly assessed the reproductive, endocrine, developmental, metabolic, cardiovascular, and immune systems. Animal evidence (available for 40 PFAS) commonly assessed effects in the reproductive, developmental, urinary, immunological, and hepatic systems. Overall, 45 PFAS had evidence across animal and epidemiology data streams.Discussion: Many of the PFAS were data poor. Epidemiological and animal evidence were lacking for most of the PFAS included in our search. By disseminating this information, we hope to facilitate additional assessment work by providing the initial scoping literature survey and identifying key research needs. Future research on data-poor PFAS will help support a more complete understanding of the potential health effects from PFAS exposures. https://doi.org/10.1289/EHP10343 相似文献
37.
Natasha Y. Sheikhan Lisa D. Hawke Clement Ma Darren Courtney Peter Szatmari Kristin Cleverley Aristotle Voineskos Amy Cheung Joanna Henderson 《Revue canadienne de psychiatrie》2022,67(11):841
BackgroundYouth mental health appears to have been negatively impacted by the COVID-19 pandemic. The impact on substance use is less clear, as is the impact on subgroups of youth, including those with pre-existing mental health or substance use challenges.ObjectiveThis hypothesis-generating study examines the longitudinal evolution of youth mental health and substance use from before the COVID-19 pandemic to over one year into the pandemic among youth with pre-existing mental health or substance use challenges.MethodA total of 168 youth aged 14–24 participated. Participants provided sociodemographic data, as well as internalizing disorder, externalizing disorder, and substance use data prior to the pandemic’s onset, then every two months between April 2020–2021. Linear mixed models and Generalized Estimating Equations were used to analyze the effect of time on mental health and substance use. Exploratory analyses were conducted to examine interactions with sociodemographic and clinical characteristics.ResultsThere was no change in internalizing or externalizing disorder scores from prior to the pandemic to any point throughout the first year of the pandemic. Substance use scores during the pandemic declined compared to pre-pandemic scores. Exploratory analyses suggest that students appear to have experienced more mental health repercussions than non-students; other sociodemographic and clinical characteristics did not appear to be associated with mental health or substance use trajectories.ConclusionsWhile mental health remained stable and substance use declined from before the COVID-19 pandemic to during the pandemic among youth with pre-existing mental health challenges, some youth experienced greater challenges than others. Longitudinal monitoring among various population subgroups is crucial to identifying higher risk populations. This information is needed to provide empirical evidence to inform future research directions. 相似文献
38.
Trichodermamides A and B,cytotoxic modified dipeptides from the marine-derived fungus Trichoderma virens 总被引:4,自引:0,他引:4
Garo E Starks CM Jensen PR Fenical W Lobkovsky E Clardy J 《Journal of natural products》2003,66(3):423-426
Trichodermamides A (1) and B (2), two modified dipeptides, have been isolated from cultures of the marine-derived fungus Trichoderma virens. The trichodermamides possess a rare cyclic O-alkyl-oxime functionality incorporated into a six-membered ring. The structure of trichodermamide B was established by X-ray diffraction analysis, while the structure assignment of trichodermamide A, and determination of the absolute stereochemistry, was accomplished by spectral and chemical methods. Trichodermamide B displayed significant in vitro cytotoxicity against HCT-116 human colon carcinoma with an IC(50) of 0.32 microg/mL. 相似文献
39.
40.
Anne C. Kirchhoff PhD MPH Courtney R. Lyles PhD Mark Fluchel MD Jennifer Wright MD Wendy Leisenring ScD 《Cancer》2012,118(23):5964-5972